JP2020503017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503017A5 JP2020503017A5 JP2019533110A JP2019533110A JP2020503017A5 JP 2020503017 A5 JP2020503017 A5 JP 2020503017A5 JP 2019533110 A JP2019533110 A JP 2019533110A JP 2019533110 A JP2019533110 A JP 2019533110A JP 2020503017 A5 JP2020503017 A5 JP 2020503017A5
- Authority
- JP
- Japan
- Prior art keywords
- modified
- compound according
- nucleoside
- crrna
- modified crrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002777 nucleoside Substances 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000003835 nucleoside group Chemical group 0.000 claims 12
- 101710163270 Nuclease Proteins 0.000 claims 5
- -1 linker nucleoside compound Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 4
- 108091033409 CRISPR Proteins 0.000 claims 3
- 238000010354 CRISPR gene editing Methods 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662439828P | 2016-12-28 | 2016-12-28 | |
| US62/439,828 | 2016-12-28 | ||
| US201762491818P | 2017-04-28 | 2017-04-28 | |
| US62/491,818 | 2017-04-28 | ||
| US201762572361P | 2017-10-13 | 2017-10-13 | |
| US62/572,361 | 2017-10-13 | ||
| PCT/US2017/068642 WO2018125964A1 (en) | 2016-12-28 | 2017-12-28 | Modified crispr rna and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020503017A JP2020503017A (ja) | 2020-01-30 |
| JP2020503017A5 true JP2020503017A5 (cg-RX-API-DMAC7.html) | 2021-02-12 |
Family
ID=62710685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533110A Pending JP2020503017A (ja) | 2016-12-28 | 2017-12-28 | 修飾ｃｒｉｓｐｒ ｒｎａ及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190382751A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3562942A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020503017A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017388379A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3047330A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018125964A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| WO2020252378A1 (en) * | 2019-06-14 | 2020-12-17 | Arbor Biotechnologies, Inc. | Novel crispr dna targeting enzymes and systems |
| JP7698715B2 (ja) * | 2020-10-19 | 2025-06-25 | カリブー・バイオサイエンシーズ・インコーポレイテッド | Ｃｒｉｓｐｒ ｖ型系のためのｄｎａ含有ポリヌクレオチドおよびガイド、ならびにこれらを製造する方法および使用する方法 |
| EP4508211A2 (en) * | 2022-04-13 | 2025-02-19 | Caribou Biosciences, Inc. | Therapeutic applications of crispr type v systems |
| AU2024270764A1 (en) | 2023-05-15 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| CN116732075B (zh) * | 2023-06-09 | 2024-03-08 | 江南大学 | 一种生产2′-岩藻糖基乳糖的多层动态调控系统及其应用 |
| WO2025212120A1 (en) * | 2024-04-05 | 2025-10-09 | Arbor Biotechnologies, Inc. | Chemical modifications of guide rnas for crispr nucleases |
| WO2025231432A1 (en) * | 2024-05-03 | 2025-11-06 | Caribou Biosciences, Inc. | In vivo gene editing with crispr systems |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102271292B1 (ko) * | 2013-03-15 | 2021-07-02 | 더 제너럴 하스피탈 코포레이션 | Rna-안내 게놈 편집의 특이성을 증가시키기 위한 rna-안내 foki 뉴클레아제(rfn)의 용도 |
| US20150376587A1 (en) * | 2014-06-25 | 2015-12-31 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
| CA2969619A1 (en) * | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| US9650617B2 (en) * | 2015-01-28 | 2017-05-16 | Pioneer Hi-Bred International. Inc. | CRISPR hybrid DNA/RNA polynucleotides and methods of use |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP3313989B1 (en) * | 2015-06-29 | 2024-12-25 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
| US12065667B2 (en) * | 2016-04-16 | 2024-08-20 | Ohio State Innovation Foundation | Modified Cpf1 MRNA, modified guide RNA, and uses thereof |
| CN106244591A (zh) * | 2016-08-23 | 2016-12-21 | 苏州吉玛基因股份有限公司 | 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用 |
| KR20190082318A (ko) * | 2016-11-22 | 2019-07-09 | 인티그레이티드 디엔에이 테크놀로지스 아이엔씨. | Crispr/cpf1 시스템 및 방법 |
-
2017
- 2017-12-28 CA CA3047330A patent/CA3047330A1/en not_active Abandoned
- 2017-12-28 WO PCT/US2017/068642 patent/WO2018125964A1/en not_active Ceased
- 2017-12-28 US US16/470,464 patent/US20190382751A1/en not_active Abandoned
- 2017-12-28 AU AU2017388379A patent/AU2017388379A1/en not_active Abandoned
- 2017-12-28 JP JP2019533110A patent/JP2020503017A/ja active Pending
- 2017-12-28 EP EP17886910.3A patent/EP3562942A4/en not_active Withdrawn